[Skip to Content]
[Skip to Content Landing]
June 6, 2017

Progress Toward Achieving UNAIDS 90-90-90 in Rural Communities in East Africa

Author Affiliations
  • 1Hubert Department of Global Health, Rollins School of Public Health, Atlanta, Georgia
  • 2Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
  • 3Emory Center for AIDS Research, Atlanta, Georgia
JAMA. 2017;317(21):2172-2174. doi:10.1001/jama.2017.5704

In recent years, the results of several studies, including Human Immunodeficiency Virus (HIV) Prevention Trials Network (HPTN) 052,1 Strategic Timing of Antiretroviral Treatment (START),2 and Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa (TEMPRANO),3 have rapidly changed the global approach to HIV treatment and have raised the possibility of ending AIDS by 2030. These 3 studies demonstrated that HIV-infected persons with viral suppression receiving antiretroviral therapy (ART) do not transmit HIV to their uninfected sex partners,1 and that initiating ART resulted in net health benefits to HIV-infected persons in high-income and low-income countries regardless of CD4 lymphocyte count.2,3 In sum, ART has been shown to be beneficial for individual and public health and that “treatment is prevention.”